Novartis shareholders approve Sandoz spinoff
At an extraordinary general meeting on Friday, shareholders of the Swiss pharma giant Novartis approved the complete spinoff of Sandoz, the Basel-based group's generics and biosimilars business. The transaction will be completed on or around October 4.
Novartis shareholders will receive one Sandoz share for every five Novartis shares, the pharma group said in a statement on Friday. Shareholders also approved the reduction of the parent company’s share capital to match that of Sandoz as a result of this decision.
+ Read more about the history of Swiss pharmaExternal link
Novartis announced its intention to spin off its Sandoz subsidiary in August 2022. Sandoz will be listed on the SIX Swiss Exchange and will have a secondary listing in the US.
This news story has been written and carefully fact-checked by an external editorial team. At SWI swissinfo.ch we select the most relevant news for an international audience and use automatic translation tools such as DeepL to translate it into English. Providing you with automatically translated news gives us the time to write more in-depth articles. You can find them here.
If you want to know more about how we work, have a look here, and if you have feedback on this news story please write to english@swissinfo.ch.
In compliance with the JTI standards
More: SWI swissinfo.ch certified by the Journalism Trust Initiative
You can find an overview of ongoing debates with our journalists here . Please join us!
If you want to start a conversation about a topic raised in this article or want to report factual errors, email us at english@swissinfo.ch.